Background {#Sec1}
==========

Cystinosis is an autosomal recessive lysosomal storage disorder characterized by accumulation of cystine within all organs as a result of mutations in the *CTNS* gene (MIM 606272; GenBank NM_004937.2 17p13), which encodes the lysosomal cystine transporter cystinosin \[[@CR1]\]. The lack of functional cystinosin causes accumulation and crystallization of cystine within the lysosomes, which leads to apoptosis and tissue damage in all organs \[[@CR2], [@CR3]\]. Lysosomal cystine accumulation results in intracellular oxidative stress and may activate inflammasome-related gene expression in proximal tubular epithelial cells \[[@CR4], [@CR5]\].

The incidence of infantile nephropathic cystinosis is 1 case per 100,000--200,000 live births in the United States and Europe \[[@CR6], [@CR7]\]. Higher incidence rate is observed in selected populations with detected founder mutations \[[@CR8]\]. The most frequent and most severe form of cystinosis is infantile cystinosis (MIM 219800), presenting during the first year and progressing to end-stage kidney disease (ESKD) in the first decade of life \[[@CR1]\]. The juvenile form (MIM 219900) of cystinosis is rare and accounts for 5% of all patients with manifestation of clinical symptoms in adolescence and kidney dysfunction at variable ages, eventually leading to ESKD \[[@CR9]\]. Non-nephropathic (ocular) cystinosis (MIM 219750) is characterized by adult-onset mild photophobia caused by cystine accumulation in the cornea of the eye without renal manifestations \[[@CR10]\].

The *CTNS* gene consists of 12 exons with exons 3--12 being coding \[[@CR11]\]. *CTNS* mutations result in either complete absence or reduced cystine transporting function \[[@CR1], [@CR12]\]. The most common mutation in the Northern European population is a large 57-kb deletion, affecting the first 10 exons of *CTNS* \[[@CR12]--[@CR14]\]. Over 140 different pathogenic *CTNS* mutations have been identified in diverse world populations, including 57 missense and nonsense mutations, 23 intronic mutations, 45 deletions, 13 small insertions, 4 indels and 3 promoter region mutations \[[@CR15]\].

Specific treatment with orally administered cysteamine, which acts by depleting cystine in lysosomes, delays the progression of cystinosis to ESKD and postpones the occurrence of other extra-renal organ involvement, but without any effect on renal Fanconi syndrome \[[@CR13], [@CR16]--[@CR18]\]. Cysteamine eye drops may mitigate visual symptoms by dissolving corneal cystine crystals. Supportive treatment of renal Fanconi syndrome includes providing appropriate nutrition and substituting renal losses (these are crucial to allow satisfactory growth); correcting the electrolyte and metabolic disturbances, phosphorus, vitamin D, magnesium, carnitine and calcium replacement therapy; non-hormonal anti-inflammatory agents to increased reabsorption of sodium chloride, water and decreased urine output \[[@CR19]\].

Here we describe a patient with typical phenotype of infantile nephropathic cystinosis with elevated white blood cell (WBC) cystine levels, but initially without identified mutations in the *CTNS* gene by Restriction Fragment Length Polymorphism (RFLP) and Sanger sequencing of genomic DNA. Next we performed Real Time Polymerase Chain Reaction (RT-PCR) analysis of the CTNS mRNA transcript obtained from patient-derived fibroblasts. Based on the identified aberration of CTNS mRNA sequence we detected a novel 9-kb homozygous deletion in the *CTNS* gene and confirmed the molecular diagnosis of infantile nephropathic cystinosis in this patient.

Case presentation {#Sec2}
=================

The boy was born from consanguineous Caucasian parents at 40^th^ week of pregnancy with birth weight 4100 g and height 54 cm. There was no family history of kidney disease. His growth and developmental milestones were appropriate to his age until the age of 6 months. At the age of 7 months the child presented with weight loss from 7.0 to 6.0 kg, polydipsia and polyuria (7.9 L/m^2^ per day), and developmental delay. At the age of 9 months low serum potassium (3.3 mmol/L) and phosphorus (0.59 mmol/L) levels were revealed. At first admission at the age of 12 months the boy had full-blown Fanconi syndrome including polyuria, phosphaturia with decreased ratio of tubular maximum reabsorption rate of phosphate to estimated glomerular filtration rate (TmP/GFR), glycosuria (4+), low molecular weight proteinuria with high urinary beta-2 microglobulin level (\> 2.5 mg/L; normal \< 0.3 mg/L), increased of fractional excretion of uric acid, potassium and sodium, aminoaciduria, metabolic acidosis, growth retardation and rickets (Table [1](#Tab1){ref-type="table"}). His eGFR was in the normal range according to his age. Table 1Clinical data of patientClinical featuresResultsAge1 y1 y 9 mo2 y 10 mo3 y 11 moWeight, kg (‰)6 (\< 3)7 (\< 3)11.4 (3)13 (10)Height, сm (‰)68 (\< 3)74 (\< 3)84 (3)91 (3)Urine output, l/m^2^ (N \< 2.0)7.38.24.84.5SerumpH (N 7.35--7.45)7.37.357.447.41HCO~3~^−^, mmol/l (N 22--26)15.121.22625Sodium, mmol/l (N 135--147)131135133139Potassium, mmol/l (N 3.7--5.1)2.43.53.62.9Chloride, mmol/l (N 97--115)819910098Phosphorus, mmol/l (N 1.3--2.2)0.531.241.31.11Alkaline phosphatase, IU/l (N \< 644)9037113901097Thyroid-stimulating hormone, mIU/ml (N 0.34--5.6)5.85.45.24.7WBC cystine, nmol half-cystine/mg protein (N \< 1.0)3.51.670.08eGFR, ml/min/1.73 m^2^77.55469.769.224-h urine analysisCalcium/creatinine ratio, mmol/mmol (N \< 1.5)0.92.23.32.5TmP/GFR, mmol/mmol(N 1.15--2.44)0.30.40.90.8Tubular urate excretion, % (N \< 10%)30525939Tubular potassium excretion, % (N \< 10%)20673845Tubular sodium excretion, % (N \< 1%)1.41.21.41.1

Kidney ultrasound revealed medullary nephrocalcinosis grade 1 (single hyperechogenic areas in the pyramids of both kidneys). The slit-lamp examination did not show any cystine crystals in the cornea. To confirm the diagnosis we performed RFLP analysis of the common in the Northern European population 57-kb deletion and direct Sanger sequencing of proband's DNA. But no mutations in the coding part of the *CTNS* gene were detected. Therefore, nephropathic cystinosis was initially excluded, and excessive investigations were performed to search for other underlying causes of renal Fanconi syndrome such as Lowe syndrome, tyrosinemia, galactosemia, glycogenosis type 1, Wilson disease and mitochondrial diseases.

At the age of 21 months repeated slit-lamp examination revealed cystine crystals in the cornea in the boy. A cystine-binding protein assay showed a high free cystine content in leukocytes (Table [1](#Tab1){ref-type="table"}) confirming the diagnosis of infantile nephropathic cystinosis in our patient. Oral cysteamine therapy (1.1 g/m^2^/day) and ophthalmic solution of cysteamine hydrochloride (one drop four times daily) were started.

Twelve-month therapy resulted in improvement of growth parameters, motor development (start walking independently), normalization of electrolyte disturbances and acidosis. A cystine-binding assay showed decreased WBC cystine level. Therefore, the cysteamine dose was increased to 1.2 g/m^2^/day. At the last follow-up, at the age of 4 years a cystine-binding protein assay showed normalization of WBC levels (Table [1](#Tab1){ref-type="table"}).

Thus, the boy with phenotype of infantile cystinosis did not have mutations in the *CTNS* gene. We hypothesized that the boy might have splicing or regulatory *CTNS* mutations. To check this hypothesis we performed RT-PCR analysis of total RNA of the *CTNS* gene in the proband.

Primary fibroblasts were obtained from forearm skin biopsy as previously described by Marakhonov et al \[[@CR20]\]. The total RNA was extracted from fibroblasts by the standard Trizol-based method. cDNA was prepared with the ImPromII Reverse Transcription System (Promega, Madison, WI) according to the manufacturer's recommendations.

PCR analysis was performed on cDNA using primer pairs for amplifying the entire coding regions of the *CTNS* gene (Table [2](#Tab2){ref-type="table"}). PCR fragments were analyzed by agarose gel electrophoresis in comparison with fibroblasts of a healthy donor. All abnormal fragments were sequenced by direct Sanger sequencing. Table 2Primers for PCR amplification of the *CTNS* genePrimerSequenceCTNS-f15′-ACCTGGCGAGGCTCATGCGT-3′CTNS-r25′-ACGTTGGTCGAGCTGCCGTT-3′CTNS-f65′-GAAGACGTCGTTGCTGTTCAC-3'CTNS-r65′-GAAGACGTCGTTGCTGTTCAC-3′CTNS-f45′-GACTTCGTGGCTCTGAACCT-3'CTNS-r45′-CTCCGAAGATCAGCGTCCAC-3'CTNS-f55′-CAGCCTCCTGCAGATGTTCC-3'CTNS-r15′-TCCTAGCCCGTCCACCAGCA-3'CTNS-F15′-ATCTGGCCTCTTGCATCTCTG-3'CTNS-R15′-ACATGCTCCAGCCTCAGTCTT-3'CTNS-F25′-TCCCTGCTGCATGAGATCACT-3'CTNS-R25′-CCATCAATGCCATCTCACACCA-3'CTNS-F35′-GATCTCGGAGTGTCCAGCTAA-3'CTNS-R35′-ATCTGTGGATCAGAGGGCTG-\'

To detect possible changes in the mRNA structure of the *CTNS* we analyzed its cDNA size and sequence in patient-derived fibroblasts by RT-PCR in combination with agarose gel electrophoresis. The entire coding region of the gene was amplified as 4 overlapping PCR fragments from cDNA template originating from the patient and healthy donor. For f6 + r6 fragment, including exon 4 and exon 5 region, we detected an abnormal size in the agarose gel compared to control (Fig. [1](#Fig1){ref-type="fig"}b). Sanger sequencing of this PCR fragment confirmed the loss of exon 4 and exon 5 in the patient's mRNA. Fig. 1RT-PCR analysis of CTNS mRNA structure in the patient-derived fibroblasts. **a**. Scheme of the *CTNS* locus. Exons are depicted as rectangular vertical boxes. The entire coding region (CDS) is highlighted in blue. The positions of the exonic PCR primers are indicated by horizontal arrows. Primer sequences are depicted in Table [2](#Tab2){ref-type="table"}. **b**. PCR fragments analyzed by 1% agarose gel electrophoresis. cDNA template was derived from fibroblasts: P - patient; C - control healthy donor. PCR fragment f6 + r6 is shorter than control in case of patient's cDNA

To detect mutation region, we designed PCR primers for genomic DNA (Fig. [2](#Fig2){ref-type="fig"}a). A 9-kb homozygous deletion, spanning region from intron 3 to intron 5, was detected in patient's DNA. In order to identify the inheritance pattern we analyzed DNA of proband's mother and father. Both parents were found to be a heterozygous carrier (Fig. [2](#Fig2){ref-type="fig"}b). Fig. 2PCR analysis of the *CTNS* locus structure in the patient's genome. **a**. Scheme of the *CTNS* locus, containing deletion. Alu sequences involved in the deletion are marked in a big arrow (Alu-F (orange) and Alu-R (green)). The positions of the intronic PCR primers are indicated by horizontal arrows. **b**. PCR fragments analyzed by 1% agarose gel electrophoresis. gDNA was used as PCR template: P - patient; M - mother; F - father; C - control healthy donor. PCR fragment F2 + R2 detected a mutated allele in 3 family members (P, M and F). PCR fragment F3 + R3 detected a WT allele in 2 carrier family members (M and F). **c**. The alignment of the recombination region. Mutated allele consists of combination of Alu-F and Alu-R sequences. The identical sequence is highlighted in red

This variant NC_000017.10:g.3545967_3555253del leads to 159 nucleotides shorter mRNA, resulting in a frameshift and truncated version of *CTNS* protein p.(Glu21GlyfsTer48). Therefore, we conclude that the new allele variant should be classified as pathogenic and was uploaded in LOVD database (ID: 0000597339).

Discussion and conclusions {#Sec3}
==========================

A diagnosis of infantile nephropathic cystinosis is based upon identification of characteristic symptoms, including renal Fanconi syndrome, corneal cystine crystals, a through clinical evaluation with increased WBC cystine levels, and confirmed by molecular analysis of the *CTNS* gene \[[@CR21]\]. A prompt diagnosis of cystinosis is critical to maximize the preventive and therapeutic benefits of cystine depleting medications.

Our patient had Fanconi syndrome at the age of 7 months, but we did not find any deposition of corneal cystine crystals at the age of 1 year. Primary RFLP analysis of the common 57-kb deletion and Sanger sequencing did not reveal any pathogenic variants in the *CTNS* gene. Conventional Sanger sequence analysis can reliably detect small genetic lesions, including point mutations and small insertions/deletions, but does not detect heterozygous exonic deletions, duplications, or other rearrangements \[[@CR22]\]. Due to this fact, we decided to perform RNA analysis as a powerful diagnostic approach to detect splice site mutations and allelic dysbalance due to regulatory mutations. Therefore, we detected a novel 9-kb homozygous deletion in the *CTNS* gene at genomic DNA level, spanning region from intron 3 to intron 5.

In general, the detection rate of *CTNS* mutations in patients with clinical diagnosis of cystinosis is \~ 95% by Sanger sequencing \[[@CR15], [@CR23]\]. However, Shotelersuk et al. failed to identify mutations in the *CTNS* gene in 19% of American cystinosis patients because the *CTNS* promoter was not analyzed \[[@CR24]\]. Similar studies with analysis of the *CTNS* promoter region showed heterozygous or no mutations in 18% of Italian patients and in 6% of French patients with nephropathic cystinosis \[[@CR25], [@CR26]\].

According to Taranta et al. two novel mutations in the *CTNS* gene were detected by studying CTNS mRNA transcripts in patients without identified mutations in one or both alleles of the *CTNS* gene by traditional genomic sequencing \[[@CR27]\]. Specifically, a splicing defect and DNA duplication were identified \[[@CR27]\]. Analysis of gene transcripts is possible only in tissues with expression of this gene. Fortunately, the *CTNS* gene is expressed in various tissues and cell lines, including fibroblasts \[[@CR28]\].

Molecular analysis of the *CTNS* gene allows not only to make an early diagnosis but also can be used for genetic counseling for the family and prenatal diagnosis of the disease. Identified mutations in the *CTNS* gene can lead to loss-of-function of the protein and manifest as the severe, infantile nephropathic phenotype as observed in the proband. On the other hand, patients with intermediate or adult forms of the disease have at least one mutation allowing the residual function of cystinosin \[[@CR29]\]. Finding the *CTNS* mutation was important for the family of our patient because they were planning the second pregnancy. Both parents were heterozygous carriers of the same mutation (Fig. [2](#Fig2){ref-type="fig"}b) and the chance of having children with nephropathic cystinosis is 25% for each pregnancy. Prenatal diagnosis of cystinosis can be rapidly made by analysis of DNA extracted from the chorionic villi during the 1st trimester of pregnancy \[[@CR23]\].

Genetic analysis of the *CTNS* gene is recommended for the diagnosis of nephropathic cystinosis according to the international consensus document \[[@CR21]\]. However, in some patients with characteristic clinical features of the disease mutations in the *CTNS* gene are not detected by analysis of genomic DNA. It does not necessary exclude the diagnosis of nephropathic cystinosis in all cases and can be complemented by the examination of the CTNS mRNA transcript, which might finally establish the genetic defect in an additional number patient. Detection of mutations in the *CTNS* gene allows to early diagnosis and can be used for genetic counseling of the families.
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